Table 1 Patient characteristics
From: FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy
Baseline characteristic | All patients with baseline FDG-PET, n (%) | Patients with baseline and post-therapy FDG-PET, n (%) | P- value |
|---|---|---|---|
No. of patients | 74 | 48 | |
Age (years) | |||
Median | 57 | 56 | |
Range | 27–88 | 35–87 | |
Gender | |||
Female | 44 (59) | 26 (54) | 0.23 |
Male | 30 (41) | 22 (46) | |
T stage | |||
T1 | 24 (32) | 9 (19) | 0.02 |
T2 | 30 (41) | 24 (50) | |
T3 | 9 (12) | 6 (13) | |
T4 | 11 (15) | 9 (19) | |
N stage | |||
N0 | 47 (64) | 30 (63) | 0.53 |
N1 | 3 (4) | 2 (4) | |
N2 | 15 (20) | 8 (17) | |
N3 | 9 (12) | 8 (17) | |
M stage | |||
M0 | 72 | 46 | |
M1 | 2 | 2 | |
Stage group | |||
I | 21 (28) | 8 (17) | 0.21 |
II | 22 (30) | 18 (38) | |
IIIA | 7 (9) | 6 (13) | |
IIIB | 22 (30) | 14 (29) | |
IV | 2 (3) | 2 (4) |
